This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Eli Lilly logo is shown on one of the company's offices in San Diego ... supported by its product portfolio of diabetes, oncology and immunology therapeutics. Ilya Yuffa China has 140 million people ...

CNBC’s Angelica Peebles sits down with Lilly’s Head of Oncology, Jake Van Naarden, to discuss what’s next in Lilly’s oncology ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright ...

"Lilly has a proven track record of bringing transformative oncology medicines to market, and we are pleased that they selected our novel camptothecin technology to integrate with their efforts to ...

The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in ...